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Abstract
In line with recent advances in neural drug design
and sensitivity prediction, we propose a novel
architecture for interpretable prediction of anti-
cancer compound sensitivity using a multimodal
attention-based convolutional encoder. Our model
is based on the three key pillars of drug sensitivity:
compounds’ structure in the form of a SMILES
sequence, gene expression profiles of tumors and
prior knowledge on intracellular interactions from
protein-protein interaction networks. We demon-
strate that our multiscale convolutional attention-
based (MCA) encoder significantly outperforms a
baseline model trained on Morgan fingerprints, a
selection of encoders based on SMILES as well
as previously reported state of the art for mul-
timodal drug sensitivity prediction (R2 = 0.86
and RMSE = 0.89). Moreover, the explainability
of our approach is demonstrated by a thorough
analysis of the attention weights. We show that
the attended genes significantly enrich apoptotic
processes and that the drug attention is strongly
correlated with a standard chemical structure sim-
ilarity index. Finally, we report a case study of
two receptor tyrosine kinase (RTK) inhibitors act-
ing on a leukemia cell line, showcasing the abil-
ity of the model to focus on informative genes
and submolecular regions of the two compounds.
The demonstrated generalizability and the inter-
pretability of our model testify its potential for
in-silico prediction of anticancer compound effi-
cacy on unseen cancer cells, positioning it as a
valid solution for the development of personalized
therapies as well as for the evaluation of candidate
compounds in de novo drug design.
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1 Introduction
1.1 Motivation
Discovery of novel compounds with a desired efficacy and
improving existing therapies are key bottlenecks in the phar-
maceutical industry, which fuel the largest R&D business
spending of any industry and account for 19% of the to-
tal R&D spending worldwide (Petrova, 2014; Goh et al.,
2017). Anticancer compounds, in particular, take the lion’s
share of drug discovery R&D efforts, with over 34% of all
drugs in the global R&D pipeline in 2018 (5,212 of 15,267
drugs) (Lloyd et al., 2017). Despite enormous scientific
and technological advances in recent years, serendipity still
plays a major role in anticancer drug discovery (Hargrave-
Thomas et al., 2012) without a systematic way to accumu-
late and leverage years of R&D to achieve higher success
rates in drug discovery. On the other hand, there is strong
evidence that the response to anticancer therapy is highly de-
pendent on the tumor genomic and transcriptomic makeup,
resulting in heterogeneity in patient clinical response to an-
ticancer drugs (Geeleher et al., 2016). This varied clinical
response has led to the promise of personalized (or pre-
cision) medicine in cancer, where molecular biomarkers,
e.g., the expression of specific genes, obtained from a pa-
tient’s tumor profiling may be used to choose a personalized
therapy.
These challenges highlight a need across both pharmaceu-
tical and healthcare industries for multimodal quantitative
methods that can jointly exploit disparate sources of knowl-
edge with the goal of characterizing the link between the
molecular structure of compounds, the genetic and epi-
genetic alterations of the biological samples and drug re-
sponse (De Niz et al., 2016). In this work, we present a
multimodal attention-based convolutional encoder that en-
ables us to tackle the aforementioned challenges.
1.2 Related work
There have been a plethora of works on the prediction of
drug sensitivity in cancer cells (Garnett et al., 2012; Yang
et al., 2012; Costello et al., 2014; Ali & Aittokallio, 2018;
Kalamara et al., 2018). While the majority of them have
focused on the analysis of unimodal datasets (genomics
or transcriptomics, e.g., De Niz et al. (2016); Tan (2016);
Turki & Wei (2017); Tan et al. (2018)), a handful of pre-
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vious works have integrated omics and chemical descrip-
tors to predict cell line-drug sensitivity using a variety of
methods including but not limited to: simple neural net-
works (one hidden layer) and random forests (Menden et al.,
2013), kernelized Bayesian matrix factorization (Ammad-
Ud-Din et al., 2014), Pearson correlation-based similarity
networks (Zhang et al., 2015), a Kronecker product kernel in
conjunction with SVMs (Wang et al., 2016), autoencoders in
combination with elastic net and SVMs (Ding et al., 2018),
matrix factorization (Wang et al., 2017), trace norm reg-
ularization (Yuan et al., 2016), link predictions (Stanfield
et al., 2017) and collaborative filtering (Liu et al., 2018;
Zhang et al., 2018b). In addition to genomic and chemi-
cal features, previous studies have demonstrated the value
of complementing drug sensitivity prediction models with
prior knowledge in the form of protein-protein interactions
(PPI) networks (Oskooei et al., 2018b). For example, in
a network-based per-drug approach integrating these data
sources, Zhang et al. (2018a) surpassed various earlier mod-
els and reported a performance drop of 3.6% when exclud-
ing PPI information.
However, all previous attempts at incorporating chemical
information in drug sensitivity prediction rely on molec-
ular fingerprints as chemical descriptors. Traditionally,
fingerprints were applied extensively for drug discovery,
virtual screening and compound similarity search (Cereto-
Massagué et al., 2015), but it has recently been argued that
the usage of engineered features constraints the learning
ability of machine learning algorithms (Goh et al., 2017).
Furthermore, for many applications, molecular fingerprints
may not be relevant, informative or even available.
With the rise of deep learning methods and their proven abil-
ity to learn the most informative features from raw data, ma-
chine learning methods used in molecular design and drug
discovery have also experienced a shift (Chen et al., 2018;
Wu et al., 2018; Grapov et al., 2018). For instance, compu-
tational chemists borrowed methods from neural language
models (Bahdanau et al., 2014) to encode SMILES strings of
molecules and predict chemical properties of molecules (Jas-
trze˛bski et al., 2016; Goh et al., 2017; Schwaller et al.,
2018b). Once a gold standard in sequence modeling, recur-
rent neural networks were initially employed as SMILES
encoders (Goh et al., 2017; Bjerrum, 2017; Segler et al.,
2017). However, it has been recently shown that convo-
lutional architectures are superior to RNNs for sequence
modeling (Bai et al., 2018), and specifically for modeling
the SMILES string encoding of compounds (Kimber et al.,
2018). It is noteworthy that these findings are in agreement
with our model comparison results that reveal convolutional
architectures are superior for SMILES sequence modeling.
Most recently, Chang et al. (2018) adopted deep learning
methods to develop a pan-drug model for predicting IC50
drug sensitivity of drug-cell line pairs. Utilizing > 30,000 bi-
nary features (∼3,000 for the molecular drug fingerprint and
the rest for a genomic fingerprint), they employ a model en-
semble of 5 deep convolutional networks (4 are completely
linear) with convolutions applied separately to each of the
genomic and molecular features before the encodings are
merged. While working towards a common goal, our ap-
proaches are vastly different. Our method presents several
key advantages: First, our algorithm ingests raw informa-
tion (SMILES string representation) which in turn enables
data augmentation and boosts model performance (Bjerrum,
2017). Secondly, we apply convolutions only on SMILES
representations for which convolutions are meaningful (i.e.,
convolutions combine information from various molecular
substructures). In accordance with Costello et al. (2014),
we use transcriptomic features (gene expression profiles)
instead of genomic features. Moreover, we combine tran-
scriptomic and molecular information using a contextual
attention encoder that renders our model transparent and in-
terpretable, a feature that is paramount in precision medicine
and has only recently started to be tackled (Yang et al., 2018).
An additional key advantage of our approach is our strict
splitting strategy and evaluation criterion. While previous
works relied on lenient splitting strategies that ensured no
drug-cell line pair in the test data was seen during training,
we adopt a more stringent splitting strategy and deprive the
model training of all drugs and cell lines that are present in
the test dataset. Our strict training and evaluation strategy
results in a significantly more challenging problem but in
turn ensures the model is learning generalizable molecu-
lar substructures with anticancer properties as opposed to
memorizing drug sensitivity from cell-drug pairs that it has
encountered during training. A model that has been trained
with such a criterion will generalize better to completely
unseen drugs and cell lines thus paving the way for both,
in silico validation of de novo drug candidates in pharma-
ceutics and selection of a suitable therapy in personalized
medicine. A lenient split, on the other hand, may facilitate
drug repositioning, as it performs best when drug and cell
line have been encountered during training.
1.3 Scope of the presented work
In this work we build upon our previous work on multi-
modal drug sensitivity prediction using attention-based en-
coders (Oskooei et al., 2018a), and propose a novel best-
performing architecture, an attention-based multiscale con-
volutional encoder. In addition, we perform a thorough
validation of the attention weights given by our proposed
MCA model. We combine 1) cell line data, 2) molecular
structure of compounds and 3) prior knowledge of protein
interactions to predict drug sensitivity. Specifically, for 1)
we explore the usage of gene expression profiles and for
2) we explore different neural architectures in combina-
tion with our devised contextual attention architecture to
encode raw SMILES of anticancer drugs in the context of
the cell that they are acting on (see Figure 1). We show
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Figure 1. The multimodal end-to-end architecture of the pro-
posed encoders. General framework for the explored architec-
tures. Each model ingests a cell-compound pair and makes an
IC50 drug sensitivity prediction. Cells are represented by the gene
expression values of a subset of 2,128 genes, selected according to
a network propagation procedure. Compounds are represented by
their SMILES string (apart from the baseline model that uses 512-
bit fingerprints). The gene-vector is fed into an attention-based
gene encoder that assigns higher weights to the most informative
genes. To encode the SMILES strings, several neural architectures
are compared and used in combination with the gene expression
encoder in order to predict drug sensitivity.
that attention-based SMILES encoders significantly surpass
a baseline feedforward model utilizing Morgan (circular)
fingerprints (Rogers & Hahn, 2010) (p < 1e-6 on RMSE).
Using our multiscale convolutional attentive (MCA) en-
coder, we show that we achieve superior IC50 prediction
performance on the GDSC database (Iorio et al., 2016)
compared with the existing methods (Menden et al., 2013;
Chang et al., 2018). Utilizing SMILES representations is
highly desirable, as they are ubiquitously available and more
interpretable than traditional fingerprints. Furthermore, our
contextual attention mechanism emerges as the key compo-
nent of our proposed SMILES encoder, as it helps validate
our findings by explaining the model’s inner working and
reasoning process, many of which are in agreement with
domain-knowledge on biochemistry of cancer cells.
2 Methods
2.1 Data
Throughout this work, we employed drug sensitivity data
from the the publicly available Genomics of Drug Sensi-
tivity in Cancer (GDSC) database (Iorio et al., 2016). The
database includes the screening results of more than a thou-
sand genetically profiled human pan-cancer cell lines with
a wide range of anticancer compounds (both chemothera-
peutic drugs and targeted therapeutics). The drug sensitivity
values were represented by half maximal inhibitory concen-
tration (IC50, i.e., the micromolar concentration of a drug
necessary to inhibit 50% of the cells) on the log-scale. We
focused on targeted drugs with publicly available molecular
structure (208 compounds of 265 in total) and retrieved the
molecular structure of the compounds from PubChem (Kim
et al., 2018) and the LINCS database. From the collected
canonical SMILES, Morgan fingerprints were acquired us-
ing RDKit (512-bit with radius 2). Exploiting the property
that most molecules have multiple valid SMILES strings,
the data augmentation strategy proposed by Bjerrum (2017)
was adopted to represent each anticancer compound with 32
different SMILES strings. We chose to represent each cell
by its transcriptomic profile as it has been demonstrated that
transcriptomic data are more predictive of drug sensitivity
when compared to other omic data (Costello et al., 2014).
As such, all available RMA-normalized gene expression
data were retrieved from the GDSC database resulting in
transcriptomic profiles of 985 cell lines in total.
2.2 Network propagation
Each of the 985 cell lines was initially represented by the ex-
pression levels of 17,737 genes which we then reduced to a
subset of 2128 genes through network propagation over the
STRING protein-protein interaction (PPI) network (Szklar-
czyk et al., 2014), a comprehensive PPI database including
interactions from multiple data sources. Following the pro-
cedure described in Oskooei et al. (2018b), STRING was
used to incorporate intracellular interactions in our model
by adopting a network propagation scheme for each drug,
where the weights associated with each of the reported tar-
gets were diffused over the STRING network (including
interactions from all the evidence types) leading to an im-
portance distribution over the genes (i.e., the vertices of the
network). Our adopted weighting and network propagation
scheme consisted of the following steps: we first assigned
a high weight (W = 1) to the reported drug target genes
while assigning a very small positive weight (ε = 1e−5)
to all other genes. Thereafter, the initialized weights were
propagated over STRING. This process was meant to inte-
grate prior knowledge about molecular interactions into our
weighting scheme, and simulate the propagation of perturba-
tions within the cell following the drug administration. Let
us denote the initial weights as W0 and the string network
as S = (P,E,A), where P are the protein vertices of the
network, E are the edges between the proteins and A is
the weighted adjacency matrix. The smoothed weights are
determined from an iterative solution of the propagation
function (Oskooei et al., 2018b):
Wt+1 = αWtA
′ + (1− α)W0 (1)
Towards Explainable Anticancer Compound Sensitivity Prediction via Multimodal Attention-based Convolutional Encoders
where D is the degree matrix and A′ is the normalized
adjacency matrix, obtained from the degree matrix D:
A′ = D−
1
2AD−
1
2 (2)
The diffusion tuning parameter, α (0 ≤ α ≤ 1), defines
how far the prior knowledge weights can diffuse through the
network. In this work, we used α = 0.7, as recommended
in the literature for the STRING network (Hofree et al.,
2013). Adopting a convergence rule of e = (Wt+1−Wt) <
1e−6, we solved Equation 1 iteratively for each drug and
used the resultant weights distribution to determine the top
20 highly ranked genes for each drug. By selecting the
top 20 genes for every drug, it was possible to compile
an interaction-aware subset of genes (2,128 genes in total).
This subset containing the most informative genes was then
used to profile each cell line in the dataset before it was
fed into our models. We limited the selection to the top
20 genes for every drug to guarantee a trade-off between
topology-awareness and the number of features describing
the biomolecular profile. We then paired all screened cell
lines and drugs to generate a pan-drug dataset of cell-drug
pairs and the associated IC50 drug response. Due to missing
values in the GDSC database, pairing of the 985 cell lines
with the 208 drugs resulted in 175,603 pairs which could be
augmented to more than 5.5 million data points following
SMILES augmentation (Bjerrum, 2017).
2.3 Model architectures
The majority of previous efforts in drug sensitivity predic-
tion focused on traditional molecular descriptors (finger-
prints). Morgan fingerprints have been shown to be a highly
informative representation for many chemical prediction
tasks (Unterthiner et al., 2014; Chang et al., 2018). We
explored several neural network SMILES encoder architec-
tures to investigate whether the molecular information of
compounds, in the context of drug sensitivity prediction,
can be learned directly from the raw SMILES rather than
using engineered fingerprints. As such, all explored encoder
architectures were compared against a baseline model that
utilized 512-bit Morgan fingerprints. The general architec-
ture of our models is shown in Figure 1.
Deep baseline (DNN). The baseline model is a 6-layered
DNN with [512, 256, 128, 64, 32, 16] units and a sigmoid
activation. The hyperparameters for the baseline model were
optimized via a cross-validation scheme (see subsection 2.4).
512-bit Morgan fingerprints and gene expression profiles
(filtered using the network propagation described in subsec-
tion 2.1) were concatenated into a joint representation from
the first layer onwards.
SMILES models (commonalities). To investigate which
model architecture best learns the molecular information of
compounds, we explored various SMILES encoders. All
SMILES-based models ingest the expression profiles and
the SMILES text encodings for the structure of the com-
pounds. The SMILES sequences were tokenized using a
regular expression (Schwaller et al., 2018a). The result-
ing atomic sequences were zero-padded and represented as
E = {e1, ..., eT }, with learned embedding vectors ei ∈ RH
for each dictionary token (see Figure 2A). Each cell line,
α jα1 αT
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... ...
tanh
T x H
T x A
A x 1
1 x A
GA Output 
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CNN output...... Gene Expression Subset
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B
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Figure 2. Key layers employed throughout the SMILES en-
coder. A) An embedding layer transforms raw SMILES strings
into a sequence of vectors in an embedding space. B) An attention-
based gene expression encoder generates attention weights that
are in turn applied to the input gene subset via a dot product. C)
A contextual attention layer ingests the SMILES encoding (either
raw or the output of another encoder, e.g., CNN, RNN and so
on) of a compound and genes from a cell to compute an attention
distribution (αi) over all tokens of the SMILES encoding, in the
context of the genetic profile of the cell. The attention-filtered
molecule represents the most informative molecular substructures
for IC50 prediction, given the gene expression of a cell.
represented by the genetic subset selected through network
propagation, is fed to the gene attention encoder (see Fig-
ure 2B). A single dense softmax layer with the same di-
mensionality as the input produces an attention weight dis-
tribution over the genes and filters them in a dot product,
ensuring most informative genes are given a higher weight
for further processing. The resulting gene attention weights
render the model interpretable, as they identify genes that
drive the sensitivity prediction for each cell line. This archi-
tecture was also investigated for the deep baseline model
but discarded due to inferior performance. All SMILES
encoders were followed by a set of dense layers (as shown
in Figure 1) with dropout (pdrop = 0.5) for regularization
and sigmoid activation function. The regression was com-
pleted by a single neuron with linear activation (rather than
sigmoid) to avoid restricting the values between 0 and 1 and
hinder the learning process of the network as a result.
Bidirectional recurrent (bRNN). RNNs have traditionally
been the first-line approach for sequence encoding. To
investigate their effectiveness in encoding SMILES, we
adopted a 2-layered bidirectional recurrent neural network
(bRNN) with gated recurrent units (GRU) (Cho et al., 2014).
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Figure 3.Model architecture of the multiscale convolutional at-
tentive (MCA) encoder. The MCA model employed 3 parallel
channels of convolutions over the SMILES sequence with kernel
sizes K and one residual channel operating directly on the token
level. Each channel applied a separate gene attention layer, before
(convoluted) SMILES and filtered genes were fed to a multihead
of 4 contextual attention layers. The output of these 16 layers were
concatenated and resulted in an IC50 prediction through a stack of
dense layers. For CA, GA and SE, see Figure 2.
The final states of the forward and backward GRU-RNN
were concatenated and fed to the dense layers for IC50
prediction.
Stacked convolutional encoder (SCNN). Next, we em-
ployed an encoder with four layers of stacked convolutions
and sigmoid activation function. 2D convolution kernels in
the first layer collapsed the embedding vectors’ hidden di-
mensionality while subsequent 1D convolutions extracted in-
creasingly long-range dependencies between different parts
of the molecule. As a result, similarly to the bRNN, any
output neuron of the SCNN SMILES encoder had integrated
information from the entire molecule.
Self-attention (SA). We investigated several encoders that
leveraged neural attention mechanisms, originally intro-
duced by Bahdanau et al. (2014). Interpretability is
paramount in healthcare and drug discovery (Koprowski
& Foster, 2018). As such, neural attention mechanisms
are central in our models as they enable us to explain and
interpret the observed results in the context of underlying
biological and chemical processes. Our first attention con-
figuration is a self-attention (SA) mechanism adapted from
document classification (Yang et al., 2016) for encoding
SMILES strings. The SMILES attention weights αi were
computed per atomic token as:
αi =
exp(ui)∑T
j exp(uj)
where ui = V T tanh(Wesi+b) (3)
The matrix We ∈ RA×H and the bias vector b ∈ RA×1 are
learned in a dense layer. si is an encoding of the i-th token
of the molecule, in the most basic case simply the SMILES
embedding ei. In all attention mechanisms, the encoded
smiles are obtained by filtering the inputs with the attention
weights.
Contextual-attention (CA). Alternatively, we devised a
contextual attention (CA) mechanism that utilizes the gene
expression subset G as a context (Figure 2C). The atten-
tion weights αi are determined according to the following
equation :
ui = V
T tanh(Wesi+WgG) where Wg ∈ RA×|G| (4)
First, the matrices Wg and We project both genes G and
the encoded SMILES tokens si into a common attention
space, A. Adding the gene context vector to the projected
token ultimately yields an αi that denotes the relevance of a
compound substructure for drug sensitivity prediction, given
a gene subset G.
Multiscale convolutional attention (MCA). In their sim-
plest form, the attention mechanisms of the SA and CA
model operates directly on the embeddings, disregarding
positional information and long-range dependencies. In-
stead they exploit the frequency counts on individual tokens
(atoms, bonds). Interestingly, the attention models neverthe-
less outperform the bRNN and SCNN which integrated in-
formation from the entire molecule. In order to combine the
benefits of the attention-based models, i.e., interpretability
with the ability of sequence encoders to extract both local
and long-range dependencies, we devised the multiscale
convolutional attentive (MCA) encoder shown in Figure 3.
Using MCA, the SMILES string of a compound is analyzed
using three separate channels, each convolving the SMILES
embeddings with a set of f kernels of sizes [H , 3], [H , 5]
and [H , 11] and ReLU activation. The efficacy of a drug
may be tied primarily to the occurrence of a specific molec-
ular substructure. MCA is designed to capture substructures
of various size using its variable kernel size. For instance,
a particular kernel could detect a steroid structure, typical
across anticancer molecules (Gupta et al., 2013). Following
the multiscale convolutions, the resulting feature maps of
each channel were fed into a contextual attention layer that
received the filtered genes as context. Similarly to Vaswani
et al. (2017), we employed m = 4 contextual attention lay-
ers for each channel, in order to allow the model to jointly
attend several parts of the molecule. The multi-head at-
tention approach, counteracts the tendency of the softmax
Towards Explainable Anticancer Compound Sensitivity Prediction via Multimodal Attention-based Convolutional Encoders
to filter out the vast majority of the sequence steps (Li &
Maki, 2018). In a fourth channel, the convolutions were
skipped (residual connection) and the raw SMILES embed-
dings were directly fed to the parallel CA layers. The output
of these 4m layers were concatenated before given to the
stack of dense feedforward layers.
2.4 Model evaluation
Strict split. To benchmark the different proposed archi-
tectures, a strict data split approach was adopted to ensure
neither the cell lines nor the compound structures within
the validation or test datasets have been seen by our models
prior to validation or testing. This is in contrast to previously
published pan-drug models which have explored only a le-
nient splitting strategy, where both compound and cell-line
of any sample in the test dataset were encountered during
training. In our data split strategy, 10% subsets of the to-
tal number of 208 compounds and 985 cell lines from the
GDSC database were set aside to be used as an unseen test
dataset to evaluate the trained models. The remaining 90%
of compounds and cell lines were then used in a 25-fold
cross-validation scheme for model training and validation.
In each fold, 4% of the drugs and 4% of cell lines were
separated and used to generate the validation dataset and the
remaining drugs and cell lines were paired and fed to the
model for training. In practice, this strategy deprived the
model from a significant proportion of samples which were
not sorted into any of training, validation or testing data.
We decided to choose 25-fold cross-validation because: 1)
this number is large enough to employ tests of statistical
significance across different models and 2) To increase the
size of the training set and in turn improve the performance
of the trained models by decreasing the number of pairs that
were excluded from training set (i.e., the validation set).
Lenient split. To compare our model with prior works that
chose a less strict data split strategy, we adopted a similar
strategy that rather than depriving the model from both the
cells and drugs in the test set, ensured no cell-drug pair in
the test set has been seen before. The new split consisted
of a standard 5-fold cross-validation scheme, wherein 10%
of the pairs (175,603 pairs from 985 cell lines and 208
drugs) were set aside for testing. IC50 values of the training
data were normalized to [0, 1] and the same transformation
was applied to validation and test data. Gene expression
values in the training set were standardized and the same
transformation was applied to the gene expression in the
validation and test sets.
2.5 Training procedure
All described architectures were implemented in
TensorFlow 1.10 with a MSE loss function that was
optimized with Adam (β1 = 0.9, β2 = 0.999, ε = 1e−8)
and a decreasing learning rate (Kingma & Ba, 2014). An
embedding dimensionality of H = 16 was adopted for
all SMILES encoders. The attention dimensionality was
set to A = 256 for the SA and CA model, while A = f
= 64 for MCA. In the final dense layers of all models
we employed dropout (pdrop = 0.5), batch normalization
and a sigmoid activation. All models were trained with
a batch size of 2,048 for a maximum of 500k steps on a
cluster equipped with POWER8 processors and an NVIDIA
Tesla P100.
3 Results
3.1 Model performance comparison on strict split
Table 1 compares the test performance of all models trained
using a 25-fold cross-validation scheme. As shown in Ta-
Table 1. Performance of the explored architectures on test
data following 25-fold cross-validation. The median Root Mean
Square Error (RMSE) and the Interquartile Range (IQR) between
predicted and true IC50 values on test data of all 25 folds are re-
ported. Interestingly, attention-based models outperform all other
models including models trained on fingerprints with a statisti-
cally significant margin (* indicating a significance of p < 0.01
compared to the DNN encoder, ** to the MCA).
Encoder type Drug Standardized RMSEstructure Median ± IQR
Deep baseline (DNN) Fingerprints 0.122 ± 0.010
Bidirectional recurrent (bRNN) SMILES 0.119 ± 0.011
Stacked convolutional (SCNN) SMILES 0.130 ± 0.006
Self-attention (SA) SMILES 0.112* ± 0.009
Contextual attention (CA) SMILES 0.110* ± 0.007
Multiscale convolutional attentive (MCA) SMILES 0.109* ± 0.009
MCA (prediction averaging) SMILES 0.104** ± 0.005
ble 1, the MCA model yielded the best performance in
predicting drug sensitivity (IC50) of unseen drugs-cell line
pairs within the test dataset. Since IC50 was normalized
to [0,1], the observed RMSE implies an average deviation
of 10.4% of the predicted IC50 values from the true val-
ues. Interestingly, the bRNN SMILES encoder matched,
but did not surpass the performance of the baseline model
(DNN). The SCNN encoder which combined and encoded
information from across the entire SMILES sequence, per-
formed significantly worse than the baseline, as assessed
by a one-sided Mann-Whitney-U test (U = 126, p < 2e-4).
We therefore hypothesize that local features of the SMILES
sequence (such as counts of atoms and bonds) contain infor-
mation most predictive of a drug’s efficacy. Attention-based
models that operated directly on the SMILES embeddings
(SA, CA), performed significantly better than all previous
models (e.g., CA vs. DNN: U = 42, p < 9e-8, SA vs. DNN:
U = 82, p < 5e-6). Surprisingly, neither complementing the
SMILES embedding with positional encodings (similarly
to Vaswani et al. (2017)) nor complementing the bRNN
encoder with attention was found to improve the model
performance. Ultimately, the MCA model was devised to
combine token-level information (benefical for the attention-
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only models) with spatially more holistic chemical features
within the same model. By architecture, some convolution
kernels in the MCA could for example develop a sensitivity
for a pyrimidine ring, potentially indicative of a tyrosine
kinase inhibitor (such as Gefitinib, Afatanib or Erlotinib); an
enzyme which inhibits phosphorylation of epidermal growth
factor receptors (EGFR) to suppress tumor cell prolifera-
tion (Jiao et al., 2018). The MCA model also outperformed
the baseline model significantly (U = 136, p < 3e-4) like an
improved version employing prediction averaging across the
20 best checkpoints did (U = 10, p < 2e-9 and U = 152, p <
9e-4 comparing to the plain MCA). In general, we observed
a strong variability across the folds, leading us to report me-
dian as a more robust measure of performance than the mean
across the folds. The variability across the folds stemmed
from the strict splitting strategy (see subsection 2.4) that
resulted in training, validation and test datasets that were
significantly different from one another. In conclusion, our
results suggest that in order to effectively capture the mode
of action of a compound, we require information from a
combination of token-level (i.e., atom or bond level) and
longer range dependencies across the SMILES sequence.
3.2 Model validation on lenient data split
In addition to the performance evaluations in Table 1, we
evaluated the MCA model using a less strict data split
strategy comparable to what had been adopted in previ-
ous works (Chang et al., 2018). This allowed for a more
meaningful comparison between the performance of our
models with existing prior art. As Figure 4 shows, the MCA
model ensemble achieved a RMSE of 0.887 on the log-IC50-
scale, corresponding to a deviation of 4.6%. The explained
variance of 86.19% suggests that our model learned to a
significant extent to predict the IC50 value of an unknown
pair, when both the cell line and drugs in the test set were
not excluded from the training set. In addition, we observed
that MCA’s performance on the lenient split was on par or
superior to that of existing pan-drug models (Menden et al.,
2013; Chang et al., 2018).
3.3 Attention analysis
Drug structure attention. To quantify and analyze the
drug attention on a large scale, we retrieved attention pro-
files for a panel of drug-cell line pairs where each drug has
been evaluated for all the cell lines in the set. The selected
panel consisted of 150 drugs and 200 cell lines. For each
drug, we defined a matrix of pairwise Euclidean distances
between the attention profiles of the treated cell lines. The
resulting distance matrix quantifies the variation in attention
profiles of a drug as a function of the treated cell lines. We
then computed, for each pair of drugs, the Frobenius dis-
tance between the attention distance matrices defined above.
Finally, we evaluated the correlation between the Frobenius
distances of each pair of drugs and their Tanimoto coeffi-
cient (Tanimoto, 1958), an established index for evaluating
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Figure 4. Test performance ofMCA on lenient splitting. Scatter
plot of correlation between true and predicted drug sensitivity by a
late-fusion model ensemble of all five folds. RMSE refers to the
plotted range, since the model was fitted in log space.
drug similarity based on fingerprints (Bajusz et al., 2015).
This approach resulted in a Pearson correlation of ρ =0.64
(n = 22500, p < 1e-50). The fact that the attention similarity
of any two drugs is highly correlated with their structural
similarity indicates that the model indeed learns valuable
insights on structural properties of compounds.
Gene attention. In order to thoroughly validate the gene
attention weights, we computed the attention profiles of all
cell lines in the test data, averaged the attention weights and
filtered them by discarding genes with negligible attention
values (ai < 1K , where K is the number of genes in the
panel). Based on the resulting subset of 371 highly attended
genes, we performed a pathway enrichment analysis using
Enrichr (Chen et al., 2013; Kuleshov et al., 2016). The
goal was to identify relevant processes highlighted by the
genes the model learned to focus on. The analysis revealed
a significant activation (adjusted p < 0.004) of the apopto-
sis signaling pathway in PANTHER (Mi et al., 2016). In
essence, drug sensitivity prediction is connected to apopto-
sis and our analysis suggests that the model learns to focus
on genes associated with key molecular processes elicited
by anticancer compounds, e.g., programmed cellular death.
A case study: two TK inhibitors. As a further valida-
tion, we analyzed in detail the neural attention mechanism
of the best MCA model (lenient split) for two very simi-
lar anticancer compounds (Imatinib and Masitinib) which
only differ in one functional group: a Thiazole ring for
Masitinib instead of a Piperazine ring for Imatinib. Both
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Figure 5. Neural attention on molecules and genes. The molec-
ular attention maps on the top demonstrate how the model’s atten-
tion is shifted when the Thiazole group is replaced by a Piperazine
group. The change in attention across the two molecules is partic-
ularly concentrated around the affected rings, signifying that these
functional groups play an important role in the mechanism of ac-
tion for these tyrosine-kinase-inhibitors when they act on a chronic
myelogenous leukemia (CML) cell line. The gene attention plot at
the bottom depicts the most attended genes of the CML cell line,
all of which can be linked to leukemia (details see text).
studied drugs are tyrosine-kinase-inhibitors that are pre-
dominantly applied in haematopoietic and lymphoid tissue.
Generally, their IC50 values are highly correlated, particu-
larly for their target cell lines (ρ = 0.72). Figure 5 depicts
the attention over both molecules when paired with cell line
MEG-01 (COSMIC ID 1295740, a type of chronic myel-
ogenous leukemia). Leukemia is targeted quite successfully
by both drugs, with Imatinib (IC50 = 81nM) being superior
to Masitinib (223nM). Comparing the attention weights on
both molecules depicted in Figure 5 reveals that the atten-
tion weights on the affected functional groups (encircled)
are drastically different in the two compounds whereas the
remaining regions of the both molecules are primarily un-
affected. The localized discrepancy in attention centered at
the affected rings suggests that these substructures are of
primary importance to the model in predicting the sensitivity
of the MEG-01 cell line to Imatinib and Masitinib.
At the bottom of Figure 5 the most attended genes of the
studied leukemia cell line and their STRING protein neigh-
borhoods are presented. Interestingly, the DDR1 protein is
a member of receptor tyrosine kinases (RTKs), the same
group of cell membrane receptors that both Imatinib and
Masitinib inhibit (Kim et al., 2011). DDR1 gene is highly
expressed in various cancer types, such as in chronic lym-
phocytic leukaemia (Barisione et al., 2017). In addition,
BMP2K gene has been recently shown to be implicated
in chronic lymphocytic leukemia (CLL) (Pandzic et al.,
2016), while CHST11 has long been known to be dereg-
ulated in CLL (Schmidt et al., 2004). TNFSF11 encodes
RANKL which is part of a prominent cancer signalling path-
way (Renema et al., 2016) and TNFSF11 has been reported
to be the most overexpressed gene in a sample of n = 129
acute lymphoblastic leukemia (ALL) patients (Heltemes-
Harris et al., 2011). RRP9 has been shown to be crucial in
treating ALL (Rainer et al., 2012)). In conclusion, the prior
knowledge from the cancer literature validate our findings
and indicate that the genes that were given the highest atten-
tion weights by our model are indeed crucial players in the
progression and treatment of leukemia.
4 Discussion
We presented an attention-based multimodal neural ap-
proach for explainable drug sensitivity prediction using a
combination of 1) SMILES string encoding of drug com-
pounds 2) transcriptomics of cancer cells and 3) intracellular
interactions incorporated into a PPI network. In an exten-
sive comparative study of SMILES sequence encoders, We
demonstrated that using the raw SMILES string of drug
compounds, we were able to surpass the predictive per-
formance reached by a baseline model utilizing Morgan
fingerprints. In addition, we demonstrated that the attention-
based SMILE encoder architectures, especially the newly
proposed MCA, performed the best while producing results
that were verifiably explainable. The validity of the drug
attention has been corroborated by demonstrating its strong
correlation with a well established structure similarity mea-
sure. To further improve the explainabiltiy of our models,
we devised a gene attention mechanism that acts on genetic
profiles and focuses on genes that are most informative for
IC50 prediction. We validated the correctness of the gene
attention weights performing a pathway enrichment analysis
over all the cell lines contained in GDSC and finding a sig-
nificant enrichment of apoptotic processes. In a case study
on a leukemia cell line we have showcased how our model
is able to focus on relevant compounds’ structural elements
and consider genes relevant for the disease of interest.
A key feature of our models was the strict training and eval-
uation strategy that set our work apart from previous art. In
our strict model evaluation approach, cells and compounds
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were split in training, validation and test dataset before
building the pairs, ensuring neither cells nor compounds in
the validation or test datasets were ever seen by the trained
model, thus depriving the model from a significant portion
of available samples. Despite this unforgiving evaluation cri-
terion, our best model (MCA) achieved an average standard
deviation of 0.11 in predicting normalized IC50 values for
unseen drug-cell pairs. Furthermore, in a separate compara-
tive study on the same dataset, this time with a lenient data
split and model evaluation criterion, we demonstrated that
our MCA model outperformed previously reported state-of-
the-art results by achieving a RMSE of 0.89 and a R2 of 86%.
We envision our attention-based approach to be of great util-
ity in personalized medicine and de novo anticancer drug
discovery where explainable prediction of drug sensitivity
is paramount. Furthermore, having established a solid mul-
timodal predictive model we have paved the way for future
directions such as: 1) Drug repositioning applications as our
model enables drug sensitivity prediction for any given drug-
cell line pair. 2) Leveraging our model in combination with
recent advances in small molecule generation using gener-
ative models (Kadurin et al., 2017; Blaschke et al., 2017)
and reinforcement learning (Popova et al., 2018) to design
novel disease-specific, or even patient-specific compounds.
This opens up a scenario where personalized treatments and
therapies can become a concrete option for patient care in
cancer precision medicine.
5 Availability of software and materials
The data in TFRecord format used in the benchmark studies
conducted in this work can be downloaded at the follow-
ing url: https://ibm.biz/paccmann-data. Alter-
natively the reader can access the raw cell line data from
GDSC (Iorio et al., 2016) and the compound structural infor-
mation from PubChem (Kim et al., 2018) and the LINCS
database.
The implementation of the models used in the benchmark
is available in the form of a toolbox on Github a the fol-
lowing link: https://github.com/drugilsberg/
paccmann.
Furthermore, the best MCA model has been deployed as a
service on IBM Cloud. Users can access the app and provide
a compound in SMILES format to obtain a prediction of its
efficacy in terms of IC50 on 970 cell lines from GDSC. The
results on drug sensitivity together with the top-attended
genes can be examined in a tabular format and downloaded
for further analysis. The service is open access and users
can register directly on the web application a the following
url: https://ibm.biz/paccmann-aas.
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